Oxaliplatin-related acute myelogenous leukemia

Benedito A. Carneiro, Lynne Kaminer, Mohammed Eldibany, Chandrika Sreekantaiah, Karen Kaul, Gershon Y. Locker*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


A 56-year-old woman diagnosed with a poorly differentiated cecal adenocarcinoma with metastases to ovaries, omentum, and sigmoid colon went into remission after 12 cycles of infusional 5-fluorouracil, luecovorin, and oxaliplatin (FOLFOX-4 regimen). Thirteen months later, a pelvic recurrence was diagnosed, and the patient received nine cycles of FOLFOX-6 plus bevacizumab, resulting in a clinical complete response but the development of pancytopenia. Bone marrow biopsy was consis tent with therapy-related acute myelogenous leukemia. Chromosome analysis showed structural rearrangements with partial deletions of the long arms of chromosomes 5, 7, 20, and 21, as well as trisomy of chromosome 8 and losses of chromosomes 3 and 11. Induction chemotherapy led to remission, but the patient died two months later from complications of colon cancer progression. It is likely that the leukemia was related to the oxaliplatin administration.

Original languageEnglish (US)
Pages (from-to)261-262
Number of pages2
Issue number3
StatePublished - Mar 2006


  • Acute myelogenous leukemia
  • Chemotherapy side effects
  • Colon adenocarcinoma therapy
  • Oxaliplatin
  • Therapy-related leukemia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Oxaliplatin-related acute myelogenous leukemia'. Together they form a unique fingerprint.

Cite this